We provide access to a unique portfolio of comprehensive genomic profiling generating high-quality somatic and germline molecular data that is analyzed and delivered as actionable medical Intelligence to empower physicians.
272 Genes TARGETED FOR CANCER-RELATED MUTATIONS
DEEPGEN™ liquid biopsy technology is proven to detect 3000 cancer-related mutations with single-molecule precision and identify cancers that would otherwise not be detected with standard screening alone.
6,000 Genes ANALYZED FOR HEREDITARY DISEASE
The exome contains 85% of all known disease causing variants. Exome sequencing is valuable in identifying hereditary genetic risk factors for disease. Our Clinical Exome looks at ~6,000 genes in the exome.
99% OF GENES RELATED TO ADVERSE DRUG REACTIONS
There are over 2 million adverse drug reactions each year in the US. Our Pharmacogenomics analyzes 44 genes covering 99% of all genes known to be associated with adverse drug reactions.
Mobile Lab Infrastructure
Our mobile laboratories are custom-built to serve specific locations or projects for businesses, the entertainment industry, government, and educational institutions. We have 100% specificity and sensitivity historically confirmed in real-world operations across ~1 million tests. Quantgene uses only our own CLIA certified and fully staffed laboratories across the United States, enabling unparalleled efficiency, reliability, and quality.